Bristol Myers Squibb (BMS) said that BMS-986278 has succeeded in lowering the rate of lung function decline in idiopathic pulmonary fibrosis patients in a phase 2 clinical trial. BMS-986278, which is an oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, is now expected to advance into phase 3 clinical development in idiopathic pulmonary fibrosis. The mid-stage […]
Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food and Drug Administration (FDA) for Abecma (idecabtagene vicleucel; ide-cel) for the treatment of relapsed or refractory multiple myeloma. The approval is for Abecma’s use in the treatment of relapsed or refractory multiple myeloma in adult patients following […]
Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with endocrine therapy, has demonstrated substantial efficacy in extending progression-free survival (PFS) for women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. This conclusion comes from a release of subgroup analyses from the […]